 Shares of Immuron Ltd. IMRN, 2.67 rocketed 49.6 in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD6.2 million 4.5 million from the U.S. Department of Defense to evaluate Travelan for military use. 